SCHEMBL2228280

SCHEMBL2228280

COCCC1(C)NC(N)=C(c2cccc(Nc3ccc(Cl)cn3)n2)O1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TSHR P16473 2/20 0.34
USP2 O75604 1/20 0.34
GRM5 P41594 1/20 0.34
SLC2A1 P11166 1/20 0.32
PDE10A Q9Y233 1/20 0.32
KDM4E B2RXH2 3/20 0.32
ALOX15 P16050 2/20 0.32
ALDH1A1 P00352 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
ALOX12 P18054 1/20 0.32
MAPK1 P28482 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2228275 0.68 KDR (0.46) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL14680970 0.68 CCNT1 (0.36) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL4898748 0.67 SLC2A1 (0.50) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL4892301 0.67 SLC2A1 (0.44) MAPTMEN1KMT2ASMN1; SMN2GRM5
SCHEMBL4903020 0.65 SLC2A1 (0.51) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL2226110 0.64 SLC2A1 (0.44) MAPTMEN1KMT2ASMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL4891120 0.63 SLC2A1 (0.62) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL4901584 0.62 SLC2A1 (0.48) MAPTMEN1KMT2ASMN1; SMN2TSHR
SCHEMBL5311907 0.62 SLC2A1 (0.40) MAPTMEN1KMT2ASMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL4896691 0.62 SLC2A1 (0.47) MAPTMEN1KMT2ASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP claimed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US claimed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US claimed
EP-2523952-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB Science (FR) 2012-11-21 EP claimed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO claimed
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SYK, LTK, MERTK MAPT 2207/4885MEN1 3607/4885KMT2A 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.